This week, the American Alliance for Biomanufacturing (AAB) and 30+ industry leaders called on Congress to include key biotech provisions in the FY26 National Defense Authorization Act (NDAA) The message is clear from NSCEB’s stark warning as highlighted in the AAB letter: “Advances in biotechnology represent a paradigm shift in how conflicts can be fought and won. The countries that seize the moment will retain or achieve superpower status. Those that fail to do so will become vulnerable to the use of biotechnology against them.” At Synonym , we stand behind this call to action and encourage industry leaders to read the full letter from AAB. Read more about the letter below. #AAB #NSCEB #FY2026 #biotech #biomanufacturing #bioeconomy
The AAB pulled together 32 other leaders in the biomanufacturing sector to advocate for the inclusion of biotechnology provisions in the FY26 National Defense Authorization Act (NDAA). As biotechnology evolves, it presents opportunities to redefine our capabilities in national security. We're at a pivotal moment – let’s ensure we put the critical pieces in place to remain global leaders in biotech and biomanufacturing. Read more: https://wix.to/qHlkH6d #Biotech #NDAA #Leadership #biomanufacturing